RxDoctor Payments Data

Daniel Decamps, MD

Family Medicine · Lake City, SCNPI 1669578373

Payments from drug & device makers

$11,132in general payments, 2019–2025

Across 653 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Amgen$690
  • Amarin Pharma, Inc.$539
  • Astellas Pharma US Inc$459
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$11,115100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,132 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$83,496
Medicare patients
234
Services billed
6,879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$92,641
EliquisApixaban83$81,710
FarxigaDapagliflozin Propanediol96$64,492
MounjaroTirzepatide50$54,550
LinzessLinaclotide62$37,777
XareltoRivaroxaban39$34,763
JardianceEmpagliflozin31$33,421
JanuviaSitagliptin Phosphate47$33,173
MyrbetriqMirabegron55$30,579
JatenzoTestosterone Undecanoate29$28,723
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,311
EntrestoSacubitril/Valsartan22$16,940
Tresiba Flextouch U-200Insulin Degludec20$16,395
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen549$15,500
MovantikNaloxegol Oxalate33$13,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,235$92,64199 claims
PfizerEliquis$241$81,71083 claims
AstraZenecaFarxiga$1,626$64,49296 claims
Lilly USA, LLCMounjaro$216$54,55050 claims
MerckJanuvia, Janumet Xr$24$40,09259 claims
AbbVieLinzess$1,848$37,77762 claims
Johnson & JohnsonXarelto$383$34,76339 claims
Boehringer IngelheimJardiance$321$33,42131 claims
Astellas Pharma US IncMyrbetriq$459$30,57955 claims
GSKTrelegy Ellipta$142$17,31127 claims
NovartisEntresto$219$16,94022 claims
Sumitomo Pharma America, Inc.Gemtesa$81$12,64319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Lake City

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →